Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Therapeutic Effect of Beta-3 Agonist and Anti-muscarinic Agent on Overactive Bladder Among Sjogren's Syndrome Patient

NCT04909255 is registered in ClinicalTrials.gov with China Medical University Hospital as lead sponsor.

NCT NCT04909255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04909255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Therapeutic Effect of Beta-3 Agonist and Anti-muscarinic Agent on Overactive Bladder Among Sjogren's Syndrome Patient
Lead sponsor
China Medical University Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
March 23, 2021
Completion date
August 15, 2022
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder syndrome, sjogren's syndrome